TY  - JOUR
AU  - Perez, Marco
AU  - Lucena-Cacace, Antonio
AU  - Marin-Gomez, Luis Miguel
AU  - Padillo-Ruiz, Javier
AU  - Robles-Frias, Maria Jose
AU  - Saez, Carmen
AU  - Garcia-Carbonero, Rocio
AU  - Carnero, Amancio
PY  - 2016
DO  - 10.18632/oncotarget.8880
UR  - http://hdl.handle.net/10668/10017
T2  - Oncotarget
AB  - Despite the development of new antineoplastic agents for the treatment of colorectal cancer (CRC), oxaliplatin and fluoropyrimidines remain the most commonly employed drugs for the treatment of both early and advanced disease. Intrinsic or acquired...
LA  - en
KW  - Src kinase
KW  - biomarkers
KW  - cancer treatment
KW  - metastatic colorectal carcinoma
KW  - pdx models
KW  - Animals
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cell Line, Tumor
KW  - Colorectal Neoplasms
KW  - Dasatinib
KW  - Drug Synergism
KW  - Female
KW  - Humans
KW  - Liver Neoplasms
KW  - Mice
KW  - Mice, Nude
KW  - Neoplasm Metastasis
KW  - Organoplatinum Compounds
KW  - Oxaliplatin
KW  - Transfection
KW  - src-Family Kinases
TI  - Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
TY  - research article
VL  - 7
ER  -